I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Van Cutsem, E.
477
results:
Search for persons
X
Format
Online (477)
Mediatypes
Articles (Online) (235)
OpenAccess-fulltext (242)
Languages
english (448)
more...
french (6)
russian (1)
less...
Sorted by: Relevance
Sorted by: Year
?
1
35P Neutropenia and efficacy outcomes in patients with refr..:
Prager, G.
;
Tabernero, J.
;
Fakih, M.
...
Annals of Oncology. 35 (2024) - p. S18-S19 , 2024
Link:
https://doi.org/10.1016/..
?
2
395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PB..:
Raymond, E.
;
Xu, J.
;
Kato, K.
...
Annals of Oncology. 35 (2024) - p. S159 , 2024
Link:
https://doi.org/10.1016/..
?
3
31P Effect of fruquintinib in patients with heavily pretrea..:
Tabernero, J.
;
Eng, C.
;
Lonardi, S.
...
Annals of Oncology. 35 (2024) - p. S15-S16 , 2024
Link:
https://doi.org/10.1016/..
?
4
77P Chronologic improvement in survival of first-line oxali..:
Takeda, Y.
;
Yamazaki, K.
;
Saltz, L.
...
Annals of Oncology. 35 (2024) - p. S38 , 2024
Link:
https://doi.org/10.1016/..
?
5
329P Nadunolimab, a first-in-class monoclonal antibody agai..:
Van Cutsem, E.
;
Ochsenreither, S.
;
Collignon, J.J.
...
Annals of Oncology. 35 (2024) - p. S138-S139 , 2024
Link:
https://doi.org/10.1016/..
?
6
323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+N..:
Macarulla Mercade, T.
;
Pazo Cid, R.A.
;
Womack, M.
...
Annals of Oncology. 35 (2024) - p. S135-S136 , 2024
Link:
https://doi.org/10.1016/..
?
7
2O Health-related quality of life (HRQoL) with first-line (..:
Lonardi, S.
;
André, T.
;
Arnold, D.
...
Annals of Oncology. 35 (2024) - p. S1-S2 , 2024
Link:
https://doi.org/10.1016/..
?
8
Clinical and molecular variables associated with early prog..:
Hulst, L.
;
Cappuyns, S.
;
Peeters, F.
...
Clinical Colorectal Cancer. , 2024
Link:
https://doi.org/10.1016/..
?
9
An open-label study of pemigatinib in cholangiocarcinoma: f..:
Vogel, A.
;
Sahai, V.
;
Hollebecque, A.
...
ESMO Open. 9 (2024) 6 - p. 103488 , 2024
Link:
https://doi.org/10.1016/..
?
10
7P Molecular targeted therapies based on metastatic site in..:
Raeisi, M.
;
Cohen, R.
;
Chibaudel, B.
...
ESMO Open. 9 (2024) - p. 102262 , 2024
Link:
https://doi.org/10.1016/..
?
11
Tislelizumab versus chemotherapy as second-line treatment f..:
Ajani, J.
;
El Hajbi, F.
;
Cunningham, D.
...
ESMO Open. 9 (2024) 1 - p. 102202 , 2024
Link:
https://doi.org/10.1016/..
?
12
Fluoropyrimidine type, patient age, tumour sidedness and mu..:
Karapetis, C. S.
;
Liu, H.
;
Sorich, M. J.
...
British Journal of Cancer. 130 (2024) 8 - p. 1269-1278 , 2024
Link:
https://doi.org/10.1038/..
?
13
Impact of KRASG12 mutations on survival with trifluridine/t..:
Tabernero, J.
;
Taieb, J.
;
Fakih, M.
...
ESMO Open. 9 (2024) 3 - p. 102945 , 2024
Link:
https://doi.org/10.1016/..
?
14
A randomized controlled trial of hand/foot-cooling by hilot..:
Coolbrandt, A.
;
Tobback, H.
;
Govaerts, R.
...
ESMO Open. 8 (2023) 2 - p. 101205 , 2023
Link:
https://doi.org/10.1016/..
?
15
155P A phase I study exploring the safety and tolerability ..:
Prenen, H.
;
Lesimple, T.
;
Robert, M.
...
Immuno-Oncology and Technology. 20 (2023) - p. 100666 , 2023
Link:
https://doi.org/10.1016/..
1-15